Please login to the form below

Not currently logged in
Email:
Password:

Wyeth shareholders approve merger

Wyeth investors have voted to approve Pfizer's proposed $68bn takeover by an overwhelming 98 per cent, according to a preliminary tally

Wyeth investors have voted to approve Pfizer's proposed $68bn takeover by an overwhelming 98 per cent, according to a preliminary tally.

The news follows the recent announcement that the European Commission has approved the deal, subject to Pfizer's pledge to shed certain animal-health assets in Europe. The deal is still subject to clearance by anti-trust regulators in the US.

New York-based Pfizer expects the deal to close by the end of the year. 

21st July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics